Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat

HIV Med. 2024 Sep;25(9):1086-1090. doi: 10.1111/hiv.13656. Epub 2024 May 9.

Abstract

Background: People living with HIV are disproportionately represented among people with severe mpox. Mild and self-limiting conjunctival involvement has been well-documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox.

Case report: Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.

Keywords: Mpox; corneal ulcer; immune reconstitution; keratitis; monkeypox; ocular complications; ophthalmology; viral infection.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents* / therapeutic use
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Mpox (monkeypox)
  • Treatment Outcome
  • Virus Shedding / drug effects

Substances

  • Antiviral Agents